Internet Stroke Center Home Stroke Trials Registry
 
National Institute of Neurological Disorders & Stroke
American Stroke Association
Washington University School of Medicine
 
 Trials Directories
Ongoing Trials
Completed Trials
Acute Stroke Trials
Hemorrhage Trials
Prevention Trials
Recovery Trials
 Interventions
Drugs - By Name
Drugs - By Category
Procedures
Recovery Therapies
 Assessment Scales
Specific Stroke Scales
Stroke Scales Overview
 Stroke Trial Links
Government Sites
Independent Sites
 News & Updates
Update List
General Stroke News
About this Site
Submit Your Trial
Send Feedback

 Search for Trials

PubMed
We comply with the "Health on the Net" (HON) code of standards for trustworthy health information: verify here.



 
Stroke Interventions in Clinical Trials
Printable Version
AESR
Amphetamine Enhanced Stroke Recovery Trial



Principal Investigator
Larry Goldstein, M.D.

PI Address
Larry Goldstein, M.D.
Neurology Division
Box 3651
DUMC
Durham, NC 27710
Phone: (919) 684-3801

Contact Email
golds004@mc.duke.edu

Sponsor



Trial Phase:Phase I
Study Size Actual:97
Study Size Planned:130
Centers Actual:5
Centers Planned:4
ISRCTN#1R01NS39934-01
Status:
As of November 2005, 97 patients had been enrolled. As of 2/4/09, this trial is on hold pending application for continued funding. We have not closed it, and the data remain un-analyzed.

Purpose:
To collect data necessary to complete the design of a full-scale clinical trial that will compare the safety and efficacy of treatment with d-amphetamine in combination with physical therapy with that of physical therapy alone in facilitating poststroke motor recovery.

Interventions:
Amphetamine
Central nervous system stimulant
Physical therapy

Location(s):
North Carolina, Missouri, New York

Year Started: 2003

Design:
Multicenter, two-part, block-randomized, placebo-controlled pilot trial.

Inclusion Criteria
Patients with motor deficits resulting from hemispheric ischemic stroke.

Patient Involvement:
Part I: N = 65
Patients will be block-randomized (according to stroke severity and vascular distribution) into treatment and control groups. The treatment group will receive d-amphetamine 10 mg/day, while the control group will receive a placebo. Every 4 days, all patients will participate in a 1-hour physical therapy session beginning 1 hour after drug or placebo administration, for a total of 6 sessions.

Part II: N = 65
Patients will also be block-randomized into treatment and control groups. Dosages will be dependent on data obtained in Part 1.

Primary Outcome:
Improvement in the Fugl-Meyer Motor score and evaluation of several secondary measures.

Results:
The premature withdrawal rate is less than half of predicted. There have been no serious, treatment-related complications.

Source of Information:
Presented at the 30th International Stroke Conference [February 2005].
Correspondence with trial coordinator [July 2005].
Presented at the 2006 International Stroke Conference [February 2006].

Web Links and Publications:
Duke Center for Cerebrovascular Disease
http://stroke.mc.duke.edu

Amphetamine Enhanced Stroke Recovery Trial: Effect of stroke location and severity on recovery rate and outcome.
http://stroke.ahajournals.org/cgi/reprint/36/2/416

Amphetamine Enhanced Stroke Recovery (AESR) Trial: Concurrent validity of the Stroke Impact Scale.
http://stroke.ahajournals.org/cgi/reprint/36/2/416

Amphetamines and related drugs in motor recovery after stroke.
Phys Med Rehabil Clin N Am 2003 Feb;14(1 Suppl):S125-34, x

Effect of cognitive impairment on recovery after ischemic stroke.
http://www3.interscience.wiley.com/cgi-bin/fulltext/111083752/PDFSTART

This information last updated on: 2/4/2009

Reviewed on: 02/04/2009.

UID: 427

   

Internet Stroke Center at Washington University:
HOME | ABOUT | PRIVACY POLICY | CONTACT

Copyright © 1997-2010 - Internet Stroke Center. All rights reserved.                                           Last modified: Friday, March 12, 2010